News
Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.
Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.
5d
Medical Device Network on MSNHelix releases pharmacogenomics tests for use in neurology and oncologyHelix has released a new suite of pharmacogenomics (PGx) tests, widening its portfolio in neurology and oncology.
The EMA's human medicines committee has said it does not recommend approval of Eli Lilly's anti-amyloid Alzheimer's disease treatment Kisunla, saying its modest benefits don't outweigh its risks.
Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...
The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug ...
Helix, a leader in precision health, is announcing the release of a new suite of pharmacogenomics (PGx) tests, including a test designed to identify patients with DYPD gene variants who may be at ...
6d
Woman's World on MSNA Dementia Diagnosis Can Take 4 Years-Here's How to Get Help FasterIf we haven't been touched by Alzheimer's directly, we know someone who has. In fact, more than 7 million Americans aged 65 ...
On July 2, the U.S. Food and Drug Administration (FDA) granted traditional approval to donanemab (Eli Lilly), sold under the brand name Kisunla, for the treatment of people living with early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results